Interim Report January - March 2009 Tripep AB (publ)

Interim Report January - March 2009 Tripep AB (publ)

•	Research and development costs amounted to SEK 1.1 (6.6) m
•	The loss after tax was SEK -3.5 (-9.9) m
•	Earnings per share were SEK -0.15 (-1.66)
•	The company had no net sales for the period
•	In a mutual understanding with the Tripep Board CEO Jan Nilsson left the
Company on March 31st. Head of Research Anders Vahlne took office as new CEO on
April 1st 
•	The last three patients have started their high-dose treatment in the
ChronVac-C® study
•	Data from the ChronVac-C® study were presented at the International Symposium
on Viral Hepatitis and Liver Diseases in Washington held between March 20 and 24
2009
•	On January 23rd the Swedish Medical Products Agency approved the start of the
phase I/II study with ChronSeal®, a study now ongoing in Norway and Sweden
•	Through Tripep's partner Kringle Pharma an option agreement has been signed
with the Japanese specialty pharma company Maruho regarding ChronSeal®


For more information, please contact:

Anders Vahlne, CEO & Head of Research, Tripep AB
Tel: +46 8 5858 1313, Mobile phone: +46 709 28 05 28
E-mail: anders.vahlne@ki.se



About Tripep
Tripep develops drugs against chronic disease based on proprietary and other
parties' patented and patent pending technologies. Tripep is focusing on the
following research projects; wound healing therapy ChronSeal® and a therapeutic
vaccine against Hepatitis C, named ChronVac-C®, plus the RAS® technology
platform. The Tripep share is admitted to trade on First North. Remium AB is
Certified Adviser for Tripep AB. For more information, please refer to the
company's website:
www.tripep.se.

In the event of any discrepancy between the Swedish and English versions of this
press release, the Swedish version will take precedence.